Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Gains from Investment Securities (2016 - 2026)

Conmed filings provide 5 years of Gains from Investment Securities readings, the most recent being $722000.0 for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities fell 81.78% to $722000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $24.1 million, a 129.04% increase, with the full-year FY2025 number at $23.0 million, changed N/A from a year prior.
  • Gains from Investment Securities hit $722000.0 in Q1 2026 for Conmed, down from $23.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $42.3 million in Q4 2024 to a low of -$27.0 million in Q3 2024.
  • Median Gains from Investment Securities over the past 4 years was $722000.0 (2026), compared with a mean of $3.2 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 1261.54% in 2024 and later soared 104.96% in 2025.
  • Conmed's Gains from Investment Securities stood at -$2.8 million in 2023, then skyrocketed by 1610.08% to $42.3 million in 2024, then plummeted by 43.69% to $23.8 million in 2025, then crashed by 96.97% to $722000.0 in 2026.
  • The last three reported values for Gains from Investment Securities were $722000.0 (Q1 2026), $23.8 million (Q4 2025), and $1.3 million (Q3 2025) per Business Quant data.